09:51 AM EST - Numinus Wellness Inc. : Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder. Numinus Wellness Inc.
shares T.NUMI are trading unchanged at $0.07.
